Article
ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.
Journal of medicinal chemistry - 12 Jan 2012
Chen Tian, Benmohamed Radhia, Kim Jinho, Smith Karen, Amante Daniel, Morimoto Richard I, Kirsch Donald R, Ferrante Robert J, Silverman Richard B
Abstract excerpt
Amyotrophic lateral sclerosis (ALS) is an orphan neurodegenerative disease currently without a cure. The arylsulfanyl pyrazolone (ASP) scaffold was one of the active scaffolds identified in a cell-based high throughput screening assay targeting mutant Cu/Zn superoxide dismutase 1 (SOD1) induced toxicity and aggregation as a marker for ALS. The initial ASP hit compounds were potent and had favorable ADME...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.